The extended spectrum beta lactamase (ESBL) producing Esherichia coli and Klebsiella spp. has become a worlwide problem. Tigecycline (the GAR-936) is a new glycylcycline antibiotic has shown in vitro activity against many multidrug-resistant pathogen. In this study, efficiency of tigecycline, amoxicillin/clavulanate, ceftazidime, ceftriaxone, cefepime, piperacillin/tazobactam, levofloxacin, minocycline, ampicillin, amikacin, meropenem were investigated using broth microdilution method in 49 (42 Esherichia coli, 7 Klebsiella spp.) ESBL-producing gram negative bacteria in bloodstream infection isolates. Antimicrobial activity were low for except amikacin, meropenem and tigecycline. MIC 50 and MIC90 values for tigecycline were determined as 0.5 μg/ml and 0.5 μg/ml and MIC range; 0.12- 1μg/ml for Esherichia coli strains, MIC range 0.5- 1 μg/ml for Klebsiella strains. Ertapenem disk-diffusion method and Modified Hodge test (MHT) were used for carbapenemase activity. In forty seven isolates were not detected for carbapenemase activity with MHT. Carbapenemase activity for two isolates could not be evaluated because of inhibitory activity.
In result of ESBL-producing gram-negative bacteria in blood cultures, all isolates were found to be susceptible to amikacin, meropenem, tigecycline, and carbapenemase activity was not determined.
Key Words: Extended Spectrum Β-Lactamase; Tigecycline; Modified Hodge Test.
|
